Fig 1.
PRISMA flow diagram.
Table 1.
Characteristics of included studies and subjects.
Table 2.
Treatment and outcome characteristics.
Fig 2.
Review author’s judgements about each risk of bias assessment presented as percentages across all included studies.
Fig 3.
Review author’s judgements about each risk of bias item for each included study.
Fig 4.
Forest plot of comparison of saroglitazar 4mg versus saroglitazar 2mg on total cholesterol (mg/dL).
Fig 5.
Forest plot of comparison of saroglitazar 4mg versus control on total cholesterol (mg/dL).
Table 3.
Mean absolute change results of all clinical outcomes measured in diabetes related dyslipidemia.
Fig 6.
Forest plot of comparison of saroglitazar 4mg versus saroglitazar 2mg on LDL-cholesterol (mg/dL).
Fig 7.
Forest plot of comparison of saroglitazar 4mg versus control on LDL-cholesterol (mg/dL).
Fig 8.
Forest plot of comparison of saroglitazar 4mg versus saroglitazar 2 mg on serum creatinine (mg/dL).